Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains.

Harris DT, Hager MV, Smith SN, Cai Q, Stone JD, Kruger P, Lever M, Dushek O, Schmitt TM, Greenberg PD, Kranz DM.

J Immunol. 2018 Feb 1;200(3):1088-1100. doi: 10.4049/jimmunol.1700236. Epub 2017 Dec 29.

PMID:
29288199
2.

Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro.

Schmitt TM, Aggen DH, Ishida-Tsubota K, Ochsenreither S, Kranz DM, Greenberg PD.

Nat Biotechnol. 2017 Dec;35(12):1188-1195. doi: 10.1038/nbt.4004. Epub 2017 Nov 6.

PMID:
29106410
3.

T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma.

Stromnes IM, Hulbert A, Pierce RH, Greenberg PD, Hingorani SR.

Cancer Immunol Res. 2017 Nov;5(11):978-991. doi: 10.1158/2326-6066.CIR-16-0322. Epub 2017 Oct 24.

PMID:
29066497
4.

A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia.

Oda SK, Daman AW, Garcia NM, Wagener F, Schmitt TM, Tan X, Chapuis AG, Greenberg PD.

Blood. 2017 Nov 30;130(22):2410-2419. doi: 10.1182/blood-2017-04-777052. Epub 2017 Oct 17.

PMID:
29042364
5.

miR-150-Mediated Foxo1 Regulation Programs CD8+ T Cell Differentiation.

Ban YH, Oh SC, Seo SH, Kim SM, Choi IP, Greenberg PD, Chang J, Kim TD, Ha SJ.

Cell Rep. 2017 Sep 12;20(11):2598-2611. doi: 10.1016/j.celrep.2017.08.065.

6.

MicroRNA-150 modulates intracellular Ca 2+ levels in naïve CD8+ T cells by targeting TMEM20.

Kim TD, Jung HR, Seo SH, Oh SC, Ban Y, Tan X, Min Kim J, Hyun Lee S, Koh DS, Jung H, Park YJ, Ran Yoon S, Doh J, Ha SJ, Choi I, Greenberg PD.

Sci Rep. 2017 Jun 1;7(1):2623. doi: 10.1038/s41598-017-02697-x.

7.

Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8+ T Cells In Vivo.

Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee C.

Sci Immunol. 2017 Feb;2(8). pii: eaal2568. doi: 10.1126/sciimmunol.aal2568. Epub 2017 Feb 24.

8.

Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.

Anderson KG, Stromnes IM, Greenberg PD.

Cancer Cell. 2017 Mar 13;31(3):311-325. doi: 10.1016/j.ccell.2017.02.008. Review.

9.

Interferon-driven deletion of antiviral B cells at the onset of chronic infection.

Fallet B, Narr K, Ertuna YI, Remy M, Sommerstein R, Cornille K, Kreutzfeldt M, Page N, Zimmer G, Geier F, Straub T, Pircher H, Larimore K, Greenberg PD, Merkler D, Pinschewer DD.

Sci Immunol. 2016 Oct 21;1(4). pii: eaah6817. doi: 10.1126/sciimmunol.aah6817.

10.

Inflammatory monocytes hinder antiviral B cell responses.

Sammicheli S, Kuka M, Di Lucia P, de Oya NJ, De Giovanni M, Fioravanti J, Cristofani C, Maganuco CG, Fallet B, Ganzer L, Sironi L, Mainetti M, Ostuni R, Larimore K, Greenberg PD, de la Torre JC, Guidotti LG, Iannacone M.

Sci Immunol. 2016 Oct 21;1(4). pii: eaah6789.

11.

Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.

Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, Schell TD, Garbi N, Greenberg PD.

Immunity. 2016 Aug 16;45(2):389-401. doi: 10.1016/j.immuni.2016.07.011. Epub 2016 Aug 9.

12.

A Public Database of Memory and Naive B-Cell Receptor Sequences.

DeWitt WS, Lindau P, Snyder TM, Sherwood AM, Vignali M, Carlson CS, Greenberg PD, Duerkopp N, Emerson RO, Robins HS.

PLoS One. 2016 Aug 11;11(8):e0160853. doi: 10.1371/journal.pone.0160853. eCollection 2016.

13.

Pancreatic Cancer: Planning Ahead for Metastatic Spread.

Stromnes IM, Greenberg PD.

Cancer Cell. 2016 Jun 13;29(6):774-776. doi: 10.1016/j.ccell.2016.05.013.

14.

T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.

Chapuis AG, Roberts IM, Thompson JA, Margolin KA, Bhatia S, Lee SM, Sloan HL, Lai IP, Farrar EA, Wagener F, Shibuya KC, Cao J, Wolchok JD, Greenberg PD, Yee C.

J Clin Oncol. 2016 Nov 1;34(31):3787-3795. doi: 10.1200/JCO.2015.65.5142.

15.

Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient.

Chapuis AG, Lee SM, Thompson JA, Roberts IM, Margolin KA, Bhatia S, Sloan HL, Lai I, Wagener F, Shibuya K, Cao J, Wolchok JD, Greenberg PD, Yee C.

J Exp Med. 2016 Jun 27;213(7):1133-9. doi: 10.1084/jem.20152021. Epub 2016 May 30.

16.

Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.

Zhang R, Verkoczy L, Wiehe K, Munir Alam S, Nicely NI, Santra S, Bradley T, Pemble CW 4th, Zhang J, Gao F, Montefiori DC, Bouton-Verville H, Kelsoe G, Larimore K, Greenberg PD, Parks R, Foulger A, Peel JN, Luo K, Lu X, Trama AM, Vandergrift N, Tomaras GD, Kepler TB, Moody MA, Liao HX, Haynes BF.

Sci Transl Med. 2016 Apr 27;8(336):336ra62. doi: 10.1126/scitranslmed.aaf0618.

17.

Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells.

Humbert O, Gisch DW, Wohlfahrt ME, Adams AB, Greenberg PD, Schmitt TM, Trobridge GD, Kiem HP.

Mol Ther. 2016 Aug;24(7):1237-46. doi: 10.1038/mt.2016.70. Epub 2016 Apr 8.

18.

Sterile inflammation induced by Carbopol elicits robust adaptive immune responses in the absence of pathogen-associated molecular patterns.

Gartlan KH, Krashias G, Wegmann F, Hillson WR, Scherer EM, Greenberg PD, Eisenbarth SC, Moghaddam AE, Sattentau QJ.

Vaccine. 2016 Apr 27;34(19):2188-96. doi: 10.1016/j.vaccine.2016.03.025. Epub 2016 Mar 19.

19.

Fresh Beginnings.

Greenberg PD, Schreiber RD, Miller LJ.

Cancer Immunol Res. 2016 Jan;4(1):1-2. doi: 10.1158/2326-6066.CIR-15-0304. No abstract available.

20.

T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.

Stromnes IM, Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen H, Cuevas C, Dotson AM, Tan X, Hotes JL, Greenberg PD, Hingorani SR.

Cancer Cell. 2015 Nov 9;28(5):638-652. doi: 10.1016/j.ccell.2015.09.022. Epub 2015 Oct 29.

21.

New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Schmitt TM, Stromnes IM, Chapuis AG, Greenberg PD.

Clin Cancer Res. 2015 Dec 1;21(23):5191-7. doi: 10.1158/1078-0432.CCR-15-0860. Epub 2015 Oct 13. Review.

22.

TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes.

Chowell D, Krishna S, Becker PD, Cocita C, Shu J, Tan X, Greenberg PD, Klavinskis LS, Blattman JN, Anderson KS.

Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):E1754-62. doi: 10.1073/pnas.1500973112. Epub 2015 Mar 23.

23.

Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10.

Finton KA, Friend D, Jaffe J, Gewe M, Holmes MA, Larman HB, Stuart A, Larimore K, Greenberg PD, Elledge SJ, Stamatatos L, Strong RK.

PLoS Pathog. 2014 Sep 25;10(9):e1004403. doi: 10.1371/journal.ppat.1004403. eCollection 2014 Sep.

24.

Molecular pathways: myeloid complicity in cancer.

Stromnes IM, Greenberg PD, Hingorani SR.

Clin Cancer Res. 2014 Oct 15;20(20):5157-70. doi: 10.1158/1078-0432.CCR-13-0866. Epub 2014 Jul 21. Review.

25.

Stromal reengineering to treat pancreas cancer.

Stromnes IM, DelGiorno KE, Greenberg PD, Hingorani SR.

Carcinogenesis. 2014 Jul;35(7):1451-60. doi: 10.1093/carcin/bgu115. Epub 2014 Jun 7. Review.

26.

MicroRNA-150 regulates the cytotoxicity of natural killers by targeting perforin-1.

Kim N, Kim M, Yun S, Doh J, Greenberg PD, Kim TD, Choi I.

J Allergy Clin Immunol. 2014 Jul;134(1):195-203. doi: 10.1016/j.jaci.2014.02.018. Epub 2014 Mar 31.

27.

Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells.

Wölfl M, Greenberg PD.

Nat Protoc. 2014 Apr;9(4):950-66. doi: 10.1038/nprot.2014.064. Epub 2014 Mar 27.

28.

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR.

Gut. 2014 Nov;63(11):1769-81. doi: 10.1136/gutjnl-2013-306271. Epub 2014 Feb 20.

29.

Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD.

Immunol Rev. 2014 Jan;257(1):145-64. doi: 10.1111/imr.12141. Review.

30.

Tolerance and exhaustion: defining mechanisms of T cell dysfunction.

Schietinger A, Greenberg PD.

Trends Immunol. 2014 Feb;35(2):51-60. doi: 10.1016/j.it.2013.10.001. Epub 2013 Nov 6. Review.

31.

Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10.

Finton KA, Larimore K, Larman HB, Friend D, Correnti C, Rupert PB, Elledge SJ, Greenberg PD, Strong RK.

PLoS Pathog. 2013;9(9):e1003639. doi: 10.1371/journal.ppat.1003639. Epub 2013 Sep 26.

32.

Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection.

Schmitt TM, Aggen DH, Stromnes IM, Dossett ML, Richman SA, Kranz DM, Greenberg PD.

Blood. 2013 Jul 18;122(3):348-56. doi: 10.1182/blood-2013-01-478164. Epub 2013 May 14.

33.

Engineering recombinant reoviruses with tandem repeats and a tetravirus 2A-like element for exogenous polypeptide expression.

Demidenko AA, Blattman JN, Blattman NN, Greenberg PD, Nibert ML.

Proc Natl Acad Sci U S A. 2013 May 14;110(20):E1867-76. doi: 10.1073/pnas.1220107110. Epub 2013 Apr 29.

34.

Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.

Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, Duerkopp N, Roberts IM, Pogosov GL, Ho WY, Ochsenreither S, Wölfl M, Bar M, Radich JP, Yee C, Greenberg PD.

Sci Transl Med. 2013 Feb 27;5(174):174ra27. doi: 10.1126/scitranslmed.3004916.

36.

Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.

Berrien-Elliott MM, Jackson SR, Meyer JM, Rouskey CJ, Nguyen TL, Yagita H, Greenberg PD, DiPaolo RJ, Teague RM.

Cancer Res. 2013 Jan 15;73(2):605-16. doi: 10.1158/0008-5472.CAN-12-2179. Epub 2012 Nov 27.

37.

Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer.

Chou CK, Schietinger A, Liggitt HD, Tan X, Funk S, Freeman GJ, Ratliff TL, Greenberg NM, Greenberg PD.

J Immunol. 2012 Oct 15;189(8):3936-46. doi: 10.4049/jimmunol.1201415. Epub 2012 Sep 14.

38.

Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens.

Wegmann F, Gartlan KH, Harandi AM, Brinckmann SA, Coccia M, Hillson WR, Kok WL, Cole S, Ho LP, Lambe T, Puthia M, Svanborg C, Scherer EM, Krashias G, Williams A, Blattman JN, Greenberg PD, Flavell RA, Moghaddam AE, Sheppard NC, Sattentau QJ.

Nat Biotechnol. 2012 Sep;30(9):883-8.

39.

Shaping of human germline IgH repertoires revealed by deep sequencing.

Larimore K, McCormick MW, Robins HS, Greenberg PD.

J Immunol. 2012 Sep 15;189(6):3221-30. doi: 10.4049/jimmunol.1201303. Epub 2012 Aug 3. Erratum in: J Immunol. 2014 Jan 1;192(1):534.

40.

Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.

Stromnes IM, Fowler C, Casamina CC, Georgopolos CM, McAfee MS, Schmitt TM, Tan X, Kim TD, Choi I, Blattman JN, Greenberg PD.

J Immunol. 2012 Aug 15;189(4):1812-25. doi: 10.4049/jimmunol.1200552. Epub 2012 Jul 13.

41.

Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen.

Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, Greenberg PD.

Blood. 2012 Jun 7;119(23):5492-501. doi: 10.1182/blood-2011-07-365890. Epub 2012 Apr 23.

42.

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer.

Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, Camisa B, Bondanza A, Casorati G, Ponzoni M, Ciceri F, Bordignon C, Greenberg PD, Holmes MC, Gregory PD, Naldini L, Bonini C.

Nat Med. 2012 May;18(5):807-815. doi: 10.1038/nm.2700.

43.

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW.

Blood. 2012 Apr 26;119(17):3940-50. doi: 10.1182/blood-2011-10-387969. Epub 2012 Feb 3.

44.

Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state.

Schietinger A, Delrow JJ, Basom RS, Blattman JN, Greenberg PD.

Science. 2012 Feb 10;335(6069):723-7. doi: 10.1126/science.1214277. Epub 2012 Jan 19.

45.

Ralph M. Steinman: a man, a microscope, a cell, and so much more.

Greenberg PD.

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):20871-2. doi: 10.1073/pnas.1119293109. Epub 2011 Dec 8. No abstract available.

46.

Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity.

Kim TD, Lee SU, Yun S, Sun HN, Lee SH, Kim JW, Kim HM, Park SK, Lee CW, Yoon SR, Greenberg PD, Choi I.

Blood. 2011 Nov 17;118(20):5476-86. doi: 10.1182/blood-2011-04-347526. Epub 2011 Sep 29.

47.

Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Aggen DH, Chervin AS, Schmitt TM, Engels B, Stone JD, Richman SA, Piepenbrink KH, Baker BM, Greenberg PD, Schreiber H, Kranz DM.

Gene Ther. 2012 Apr;19(4):365-74. doi: 10.1038/gt.2011.104. Epub 2011 Jul 14.

48.

Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge.

Tan X, Sande JL, Pufnock JS, Blattman JN, Greenberg PD.

J Virol. 2011 Aug;85(16):8316-27. doi: 10.1128/JVI.00781-11. Epub 2011 Jun 8.

49.

Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28.

Pufnock JS, Cigal M, Rolczynski LS, Andersen-Nissen E, Wolfl M, McElrath MJ, Greenberg PD.

Blood. 2011 Jun 16;117(24):6542-51. doi: 10.1182/blood-2010-11-317966. Epub 2011 Apr 14.

50.

Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8.

Stone JD, Aggen DH, Chervin AS, Narayanan S, Schmitt TM, Greenberg PD, Kranz DM.

J Immunol. 2011 May 1;186(9):5193-200. doi: 10.4049/jimmunol.1003755. Epub 2011 Mar 30.

Supplemental Content

Loading ...
Support Center